MTOR inhibition modulates epileptogenesis, seizures and depressive behavior in a genetic rat model of absence epilepsy

Neuropharmacology

Volumn 69, Issue , 2013, Pages 25-36

  Russo, Emilio ^a   Citraro, Rita ^a   Donato, Giuseppe ^a   Camastra, Caterina ^a   Iuliano, Rodolfo ^a   Cuzzocrea, Salvatore ^b   Constanti, Andrew ^c   De Sarro, Giovambattista ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Depressive behavior; LPS; Neuroinflammation; Rapamycin; SWDs; WAG Rij rats

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN;

ABSENCE; ACUTE DRUG ADMINISTRATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICONVULSANT ACTIVITY; ANTIDEPRESSANT ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG MEGADOSE; EARLY INTERVENTION; EPILEPTOGENESIS; MALE; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; RAT; SEIZURE;

ANIMALS; ANTICONVULSANTS; BEHAVIOR, ANIMAL; DEPRESSION; ELECTROENCEPHALOGRAPHY; EPILEPSY, ABSENCE; FEEDING BEHAVIOR; IMMUNOHISTOCHEMISTRY; LIPOPOLYSACCHARIDES; MOTOR ACTIVITY; NEUROSURGICAL PROCEDURES; RATS; RATS, WISTAR; SEIZURES; SIROLIMUS; SUCROSE; SWIMMING; TOR SERINE-THREONINE KINASES;

EID: 84875258395     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2012.09.019     Document Type: Article

References (114)

1. D. Akin, T. Ravizza, M. Maroso, N. Carcak, T. Eryigit, I. Vanzulli, R.G. Aker, A. Vezzani, and F.Y. Onat IL-1β is induced in reactive astrocytes in the somatosensory cortex of rats with genetic absence epilepsy at the onset of spike-and-wave discharges, and contributes to their occurrence Neurobiol. Dis. 44 2011 259 269
2. M.C. Angulo, A.S. Kozlov, S. Charpak, and E. Audinat Glutamate released from glial cells synchronizes neuronal activity in the hippocampus J. Neurosci. 24 2004 6920 6927
3. M. Avoli, and P. Gloor Interaction of cortex and thalamus in spike and wave discharges of feline generalized penicillin epilepsy Exp. Neurol. 76 1982 196 217
4. S. Balosso, M. Maroso, M. Sanchez-Alavez, T. Ravizza, A. Frasca, T. Bartfai, and A. Vezzani A novel non-transcriptional pathway mediates the proconvulsive effects of interleukin-1beta Brain 131 2008 3256 3265
5. M. Battaglia, A. Stabilini, E. Draghici, S. Gregori, C. Mocchetti, E. Bonifacio, and M.G. Roncarolo Rapamycin and interleukin-10 treatment induces T regulatory type 1 cells that mediate antigen-specific transplantation tolerance Diabetes 55 2006 40 49
6. H. Blumenfeld, J.P. Klein, U. Schridde, M. Vestal, T. Rice, D.S. Khera, C. Bashyal, K. Giblin, C. Paul-Laughinghouse, F. Wang, A. Phadke, J. Mission, R.K. Agarwal, D.J. Englot, J. Motelow, H. Nersesyan, S.G. Waxman, and A.R. Levin Early treatment suppresses the development of spike-wave epilepsy in a rat model Epilepsia 49 2008 400 409
7. D.R. Bolster, S.J. Crozier, S.R. Kimball, and L.S. Jefferson AMP-activated protein kinase suppresses protein synthesis in rat skeletal muscle through downregulated mammalian target of rapamycin (mTOR) signaling J. Biol. Chem. 277 2002 23977 23980
8. P.S. Buckmaster, and F.H. Lew Rapamycin suppresses mossy fiber sprouting but not seizure frequency in a mouse model of temporal lobe epilepsy J. Neurosci. 31 2011 2337 2347
9. P.S. Buckmaster, E.A. Ingram, and X. Wen Inhibition of the mammalian target of rapamycin signaling pathway suppresses dentate granule cell axon sprouting in a rodent model of temporal lobe epilepsy J. Neurosci. 29 2009 8259 8269
10. M. Cammalleri, R. Lütjens, F. Berton, A.R. King, C. Simpson, W. Francesconi, and P.P. Sanna Time-restricted role for dendritic activation of the mTOR-p70S6K pathway in the induction of late-phase long-term potentiation in the CA1 Proc. Natl. Acad. Sci. U. S. A. 100 2003 14368 14373
11. M.A. Castro-Alamancos Origin of synchronized oscillations induced by neocortical disinhibition in vivo J. Neurosci. 20 2000 9195 9206
12. C.H. Cho Frontier of epilepsy research-mTOR signaling pathway Exp. Mol. Med. 43 2011 231 274
13. R. Citraro, E. Russo, S. Gratteri, E.D. Di Paola, G.F. Ibbadu, C. Curinga, R. Gitto, A. Chimirri, G. Donato, and G. De Sarro Effects of non-competitive AMPA receptor antagonists injected into some brain areas of WAG/Rij rats, an animal model of generalized absence epilepsy Neuropharmacology 51 2006 1058 1067
14. R. Citraro, E. Russo, E.D. Di Paola, G.F. Ibbadu, S. Gratteri, R. Marra, and G. De Sarro Effects of some neurosteroids injected into some brain areas of WAG/Rij rats, an animal model of generalized absence epilepsy Neuropharmacology 50 2006 1059 1071
15. A.M. Coenen, and E.L. Van Luijtelaar Genetic animal models for absence epilepsy: a review of the WAG/Rij strain of rats Behav. Genet. 33 2003 635 655
16. ®) MEIA method Clin. Chem. Lab. Med. 48 2010 1523 1525
17. P.B. Crino mTOR: a pathogenic signaling pathway in developmental brain malformations Trends Mol. Med. 17 2011 734 742
18. L. Danober, C. Deransart, A. Depaulis, M. Vergnes, and C. Marescaux Pathophysiological mechanisms of genetic absence epilepsy in the rat Prog. Neurobiol. 55 1998 27 57
19. R. Dantzer, J.C. O'Connor, G.G. Freund, R.W. Johnson, and K.W. Kelley From inflammation to sickness and depression: when the immune system subjugates the brain Nat. Rev. Neurosci. 9 2008 46 56
20. M.G. De Simoni, and L. Imeri Cytokine-neurotransmitter interactions in the brain Biol. Signals Recept. 7 1998 33 44
21. C. Dello Russo, L. Lisi, G. Tringali, and P. Navarra Involvement of mTOR kinase in cytokine-dependent microglial activation and cell proliferation Biochem. Pharmacol. 78 2009 1242 1251
22. M.A. Dichter Models of epileptogenesis in adult animals available for antiepileptogenesis drug screening Epilepsy Res. 68 2006 31 35
23. R.S. Duman, N. Li, R.J. Liu, V. Duric, and G. Aghajanian Signaling pathways underlying the rapid antidepressant actions of ketamine Neuropharmacology 62 2012 35 41
24. J.M. Dwyer, A.E. Lepack, and R.S. Duman mTOR activation is required for the antidepressant effects of mGluR2/3 blockade Int. J. Neuropsychopharmacol. 24 2011 1 6
25. Y. Furukawa-Hibi, A. Nitta, T. Ikeda, K. Morishita, W. Liu, D. Ibi, T. Alkam, T. Nabeshima, and K. Yamada The hydrophobic dipeptide Leu-Ile inhibits immobility induced by repeated forced swimming via the induction of BDNF Behav. Brain Res. 220 2011 271 280
26. A.S. Galanopoulou, J.A. Gorter, and C. Cepeda Finding a better drug for epilepsy: the mTOR pathway as an antiepileptogenic target Epilepsia 53 2012 1119 1130
27. P. Gareri, D. Condorelli, N. Belluardo, R. Citraro, V. Barresi, A. Trovato-Salinaro, G. Mudò, G.F. Ibbadu, E. Russo, and G. De Sarro Antiabsence effects of carbenoxolone in two genetic animal models of absence epilepsy (WAG/Rij rats and lh/lh mice). Neuropharmacology 49 2005 551 563
28. M.G. Garelick, and B.K. Kennedy TOR on the brain Exp. Gerontol. 46 2011 155 163
29. J. Gomez-Cambronero Rapamycin inhibits GM-CSF-induced neutrophil migration FEBS Lett. 550 2003 94 100
30. R. Gong, C.S. Park, N.R. Abbassi, and S.J. Tang Roles of glutamate receptors and the mammalian target of rapamycin (mTOR) signaling pathway in activity-dependent dendritic protein synthesis in hippocampal neurons J. Biol. Chem. 281 2006 18802 18815
31. S. Hashioka Antidepressants and neuroinflammation: can antidepressants calm glial rage down? Mini Rev. Med. Chem. 11 2011 555 564
32. L. Hou, and E. Klann Activation of the phosphoinositide 3-kinase-Akt mammalian target of rapamycin signaling pathway is required for metabotropic glutamate receptor-dependent long-term depression J. Neurosci. 24 2004 6352 6361
33. S. Hu, W.S. Sheng, L.C. Ehrlich, P.K. Peterson, and C.C. Chao Cytokine effects on glutamate uptake by human astrocytes Neuroimmunomodulation 7 2000 153 159
34. J. Huang, and B.D. Manning The TSC1-TSC2 complex: a molecular switchboard controlling cell growth Biochem. J. 412 2008 179 190
35. Y. Huang, B.N. Kang, J. Tian, Y. Liu, H.R. Luo, L. Hester, and S.H. Snyder The cationic amino acid transporters CAT1 and CAT3 mediate NMDA receptor activation-dependent changes in elaboration of neuronal processes via the mammalian target of rapamycin mTOR pathway J. Neurosci. 27 2007 449 458
36. X. Huang, H. Zhang, J. Yang, J. Wu, J. McMahon, Y. Lin, Z. Cao, M. Gruenthal, and Y. Huang Pharmacological inhibition of the mammalian target of rapamycin pathway suppresses acquired epilepsy Neurobiol. Dis. 40 2010 193 199
37. K. Inoki, Y. Li, T. Zhu, J. Wu, and K.L. Guan TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signaling Nat. Cell. Biol. 4 2002 648 657
38. J. Jaworski, S. Spangler, D.P. Seeburg, C.C. Hoogenraad, and M. Sheng Control of dendritic arborization by the phosphoinositide-3-kinase-Akt-mammalian target of rapamycin pathway J. Neurosci. 25 2005 11300 11312
39. C.S. Jernigan, D.B. Goswami, M.C. Austin, A.H. Iyo, A. Chandran, C.A. Stockmeier, and B. Karolewicz The mTOR signaling pathway in the prefrontal cortex is compromised in major depressive disorder Prog. Neuropsychopharmacol. Biol. Psychiatry 35 2011 1774 1779
40. N.C. Jones, M.R. Salzberg, G. Kumar, A. Couper, M.J. Morris, and T.J. O'Brien Elevated anxiety and depressive-like behavior in a rat model of genetic generalized epilepsy suggesting common causation Exp. Neurol. 209 2008 254 260
41. D.H. Kim, D.D. Sarbassov, S.M. Ali, J.E. King, R.R. Latek, H. Erdjument-Bromage, P. Tempst, and D.M. Sabatini mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery Cell 110 2002 163 175
42. M.S. Kim, M. Rådinger, and A.M. Gilfillan The multiple roles of phosphoinositide 3-kinase in mast cell biology Trends Immunol. 29 2008 493 501
43. N. Kimura, C. Tokunaga, S. Dalal, C. Richardson, K. Yoshino, K. Hara, B.E. Kemp, L.A. Witters, O. Mimura, and K. Yonezawa A possible linkage between AMP-activated protein kinase (AMPK) and mammalian target of rapamycin (mTOR) signaling pathway Genes Cell. 8 2003 65 79
44. H. Koike, M. Iijima, and S. Chaki Involvement of the mammalian target of Rapamycin signaling in the antidepressant-like effect of group II metabotropic glutamate receptor antagonists Neuropharmacology 61 2011 1419 1423
45. Z. Kovács, K.A. Kékesi, N. Szilágyi, I. Abrahám, D. Székács, N. Király, E. Papp, I. Császár, E. Szego, K. Barabás, H. Péterfy, A. Erdei, T. Bártfai, and G. Juhász Facilitation of spike-wave discharge activity by lipopolysaccharides in Wistar Albino Glaxo/Rijswijk rats Neuroscience 140 2006 731 742
46. Z. Kovács, A. Czurkó, K.A. Kékesi, and G. Juhász Intracerebroventricularly administered lipopolysaccharide enhances spike-wave discharges in freely moving WAG/Rij rats Brain Res. Bull. 85 2011 410 416
47. V. Kumar, M.X. Zhang, M.W. Swank, J. Kunz, and G.Y. Wu Regulation of dendritic morphogenesis by Ras-PI3K-Akt-mTOR and Ras-MAPK signaling pathways J. Neurosci. 25 2005 11288 11299
48. U.E. Lang, J. Heger, M. Willbring, M. Domula, K. Matschke, and S.M. Tugtekin Immunosuppression using the mammalian target of rapamycin (mTOR) inhibitor everolimus: pilot study shows significant cognitive and affective improvement Transplant. Proc. 41 2009 4285 4288
49. K.A. Lehtimäki, T. Keränen, J. Palmio, R. Mäkinen, M. Hurme, J. Honkaniemi, and J. Peltola Increased plasma levels of cytokines after seizures in localization-related epilepsy Acta Neurol. Scand. 116 2007 226 230
50. L.B. Li, S.V. Toan, O. Zelenaia, D.J. Watson, J.H. Wolfe, J.D. Rothstein, and M.B. Robinson Regulation of astrocytic glutamate transporter expression by Akt: evidence for a selective transcriptional effect on the GLT-1/EAAT2 subtype J. Neurochem. 97 2006 759 771
51. G. Li, S. Bauer, M. Nowak, B. Norwood, B. Tackenberg, F. Rosenow, S. Knake, W.H. Oertel, and H.M. Hamer Cytokines and epilepsy Seizure 20 2011 249 256
52. W. Loscher, and D. Schmidt New horizons in the development of antiepileptic drugs: innovative strategies Epilepsy Res. 69 2006 183 272
53. C. Malagelada, E.J. Ryu, S.C. Biswas, V. Jackson-Lewis, and L.A. Greene RTP801 is elevated in Parkinson brain substantia nigral neurons and mediates death in cellular models of Parkinson's disease by a mechanism involving mammalian target of rapamycin inactivation J. Neurosci. 26 2006 9996 10005
54. P. Mascarucci, C. Perego, S. Terrazzino, and M.G. De Simoni Glutamate release in the nucleus tractus solitarius induced by peripheral lipopolysaccharide and interleukin-1 beta Neuroscience 86 1998 1285 1290
55. S.S. McDaniel, and M. Wong Therapeutic role of mammalian target of rapamycin (mTOR) inhibition in preventing epileptogenesis Neurosci. Lett. 497 2011 231 239
56. T.M. Melo, U. Sonnewald, I.A. Bastholm, and A. Nehlig Astrocytes may play a role in the etiology of absence epilepsy: a comparison between immature GAERS not yet expressing seizures and adults Neurobiol. Dis. 28 2007 227 235
57. L.G. Miller, W.R. Galpern, K. Dunlap, C.A. Dinarello, and T.J. Turner Interleukin-1 augments gamma-aminobutyric acid A receptor function in brain Mol. Pharmacol. 139 1991 105 108
58. J. Młodzikowska-Albrecht, B. Steinborn, and M. Zarowski Cytokines, epilepsy and epileptic drugs-is there a mutual influence? Pharmacol. Rep. 59 2007 129 138
59. A.K. Ngugi, S.M. Kariuki, C. Bottomley, I. Kleinschmidt, J.W. Sander, and C.R. Newton Incidence of epilepsy: a systematic review and meta-analysis Neurology 77 2011 1005 1012
60. E. Painsipp, M.J. Köfer, F. Sinner, and P. Holzer Prolonged depression-like behavior caused by immune challenge: influence of mouse strain and social environment PLoS One 6 2011 e20719
61. G. Paxinos, and C. Watson The Rat Brain in Stereotaxic Coordinates fourth ed. 1998 Academic Press
62. A. Pitkänen, and K. Lukasiuk Molecular biomarkers of epileptogenesis Biomark. Med. 5 2011 629 633
63. R.D. Porsolt, A. Bertin, and M. Jalfre Behavioral despair in mice: a primary screening test for antidepressants Arch. Int. Pharmacodyn. Ther. 229 1977 327 336
64. K.F. Raab-Graham, P.C.G. Haddick, Y.N. Jan, and L.Y. Jan Activity- and mTOR-dependent suppression of Kv1.1 channel mRNA translation in dendrites Science 314 2006 144 148
65. B. Ravikumar, C. Vacher, Z. Berger, J.E. Davies, S. Luo, and L.G. Oroz Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease Nat. Genet. 36 2004 585 595
66. T. Ravizza, and A. Vezzani Status epilepticus induces time-dependent neuronal and estrocytic expression of IL-1 receptor type-I in the rat limbic system Neuroscience 137 2006 301 308
67. S. Rüegg, M. Baybis, H. Juul, M. Dichter, and P.B. Crino Effects of rapamycin on gene expression, morphology, and electrophysiological properties of rat hippocampal neurons Epilepsy Res. 77 2007 85 92
68. E. Russo, A. Constanti, G. Ferreri, R. Citraro, and G. De Sarro Nifedipine affects the anticonvulsant activity of topiramate in various animal models of epilepsy Neuropharmacology 46 2004 865 878
69. E. Russo, R. Citraro, S. De Fazio, R. Marra, R. Gitto, A. Chimirri, G. De Sarro, and E.D. Di Paola Enhancement of anti-absence effects of ethosuximide by low doses of a noncompetitive alpha-amino-3-hydroxy-5-methyl-4- isoxazolepropionic acid (AMPA) receptor antagonist in a genetic animal model of absence epilepsy Epilepsy Behav. 13 2008 295 299
70. E. Russo, R. Citraro, F. Scicchitano, S. De Fazio, E.D. Di Paola, A. Constanti, and G. De Sarro Comparison of the antiepileptogenic effects of an early long-term treatment with ethosuximide or levetiracetam in a genetic animal model of absence epilepsy Epilepsia 51 2010 1560 1569
71. E. Russo, R. Citraro, F. Scicchitano, S. De Fazio, I. Perrotta, E.D. Di Paola, A. Constanti, and G. De Sarro Effects of early long-term treatment with antiepileptic drugs, on development of seizures and depressive-like behavior in a rat genetic absence epilepsy model Epilepsia 52 2011 1341 1350
72. E. Russo, R. Citraro, F. Scicchitano, A. Urzino, R. Marra, V. Rispoli, and G. De Sarro Vigabatrin has antiepileptogenic and antidepressant effects in an animal model of epilepsy and depression comorbidity Behav. Brain Res. 225 2011 373 376
73. Russo, E., Citraro, R., Constanti, A., De Sarro, G. The mTOR signaling pathway in the brain: focus on epilepsy and epileptogenesis. Mol. Neurobiol., in press.
74. E. Russo, R. Citraro, A. Davoli, L. Gallelli, E. Donato Di Paola, and G. De Sarro Ameliorating effects of aripiprazole on cognitive functions and depressive-like behavior in a genetic rat model of absence epilepsy and mild-depression comorbidity Neuropharmacology 64 2013 371 379
75. D.M. Sabatini, R.K. Barrow, S. Blackshaw, P.E. Burnett, M.M. Lai, M.E. Field, B.A. Bahr, J. Kirsch, H. Betz, and S.H. Snyder Interaction of RAFT1 with gephyrin required for rapamycin-sensitive signaling Science 284 1999 1161 1164
76. D.K. Sandsmark, C. Pelletier, J.D. Weber, and D.H. Gutmann Mammalian target of rapamycin: master regulator of cell growth in the nervous system Histol. Histopathol. 22 2007 895 903
77. K. Sarkisova, and G. van Luijtelaar The WAG/Rij strain: a genetic animal model of absence epilepsy with comorbidity of depression Prog. Neuropsychopharmacol. Biol. Psychiatry 35 2011 854 876
78. K.Y. Sarkisova, M.A. Kulikov, I.S. Midzyanovskaya, and A.A. Folomkina Dopamine-dependent nature of depression-like behavior in WAG/Rij rats with genetic absence epilepsy Neurosci. Behav. Physiol. 38 2008 119 128
79. K.Y. Sarkisova, G.D. Kuznetsova, M.A. Kulikov, and G. van Luijtelaar Spike-wave discharges are necessary for the expression of behavioral depression-like symptoms Epilepsia 51 2010 146 160
80. L.Z. Sha, X.L. Xing, D. Zhang, Y. Yao, W.C. Dou, L.R. Jin, L.W. Wu, and Q. Xu Mapping the spatio-temporal pattern of the mammalian target of rapamycin (mTOR) activation in temporal lobe epilepsy PLoS One 7 2012 e39152
81. F.Z. Shaw, S.H. Chuang, K.R. Shieh, and Y.J. Wang Depression- and anxiety-like behaviors of a rat model with absence epileptic discharges Neuroscience 160 2009 382 393
82. A. Sliwa, G. Plucinska, J. Bednarczyk, and K. Lukasiuk Post-treatment with rapamycin does not prevent epileptogenesis in the amygdala stimulation model of temporal lobe epilepsy Neurosci. Lett. 509 2012 105 109
83. A.A. Sosunov, X. Wu, R.A. McGovern, D.G. Coughlin, C.B. Mikell, R.R. Goodman, and G.M. McKhann 2nd The mTOR pathway is activated in glial cells in mesial temporal sclerosis Epilepsia 53 2012 78 86
84. L.P. Spear The adolescent brain and age-related behavioral manifestations Neurosci. Biobehav. Rev. 24 2000 417 463
85. H. Stefan, F.H. Lopes da Silva, W. Loscher, D. Schmidt, E. Perucca, M.J. Brodie, P.A. Boon, W.H. Theodore, and S.L. Moshé Epileptogenesis and rational therapeutic strategies Acta Neurol. Scand. 113 2006 139 155
86. J. Steiner, M. Walter, T. Gos, G.J. Guillemin, H.G. Bernstein, Z. Sarnyai, C. Mawrin, R. Brisch, H. Bielau, L. Meyer zu Schwabedissen, B. Bogerts, and A.M. Myint Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: evidence for an immune-modulated glutamatergic neurotransmission? J. Neuroinflammation 8 2011 94
87. L. Swiech, M. Perycz, A. Malik, and J. Jaworski Role of mTOR in physiology and pathology of the nervous system Biochim. Biophys. Acta 1784 2008 116 132
88. J. Szelenyi Cytokines and the central nervous system Brain Res. Bull. 54 2001 329 338
89. N. Takei, N. Inamura, M. Kawamura, H. Namba, K. Hara, K. Yonezawa, and H. Nawa Brain-derived neurotrophic factor induces mammalian target of rapamycin-dependent local activation of translation machinery and protein synthesis in neuronal dendrites J. Neurosci. 24 2004 9760 9769
90. S.J. Tang, G. Reis, H. Kang, A.C. Gingras, N. Sonenberg, and E.M. Schuman A rapamycin-sensitive signaling pathway contributes to long-term synaptic plasticity in the hippocampus Proc. Natl. Acad. Sci. U. S. A. 99 2002 467 472
91. S.W. Tang, D. Helmeste, and B. Leonard Is neurogenesis relevant in depression and in the mechanism of antidepressant drug action? A critical review World J. Biol. Psychiatry 13 2012 402 412
92. S.F. Tavazoie, V.A. Alvarez, D.A. Ridenour, D.J. Kwiatkowski, and B.L. Sabatini Regulation of neuronal morphology and function by the tumor suppressors Tsc1 and Tsc2 Nat. Neurosci. 8 2005 1727 1734
93. N.R. Temkin Antiepileptogenesis and seizure prevention trials with antiepileptic drugs: meta-analysis of controlled trials Epilepsia 42 2001 515 524
94. C.K. Tsang, H. Qi, L.F. Liu, and X.F.S. Zheng Targeting mammalian target of rapamycin (mTOR) for health and diseases Drug Discov. Today 12 2007 112 124
95. E.A. van Vliet, G. Forte, L. Holtman, J.C. den Burger, A. Sinjewel, H.E. de Vries, E. Aronica, and J.A. Gorter Inhibition of mammalian target of rapamycin reduces epileptogenesis and blood-brain barrier leakage but not microglia activation Epilepsia 53 2012 1254 1263
96. A. Vezzani, and A. Friedman Brain inflammation as a biomarker in epilepsy Biomark. Med. 5 2011 607 614
97. A. Vezzani, and T. Granata Brain inflammation in epilepsy: experimental and clinical evidence Epilepsia 46 2005 1724 1743
98. A. Vezzani, D. Moneta, C. Richichi, M. Aliprandi, S.J. Burrows, T. Ravizza, C. Perego, and M.G. de Simoni Functional role of inflammatory cytokines and antiinflammatory molecules in seizures and epileptogenesis Epilepsia 43 2002 30 35
99. A. Vezzani, S. Balosso, and T. Ravizza The role of cytokines in the pathophysiology of epilepsy Brain Behav. Immun. 22 2008 797 803
100. A. Vezzani, T. Ravizza, S. Balosso, and E. Aronica Glia as a source of cytokines: implications for neuronal excitability and survival Epilepsia 49 2008 24 32
101. A. Vezzani, J. French, T. Bartfai, and T.Z. Baram The role of inflammation in epilepsy Nat. Rev. Neurol. 7 2011 31 40
102. R.G. Victor, G.D. Thomas, E. Marban, and B. O'Rourke Presynaptic modulation of cortical synaptic activity by calcineurin Proc. Natl. Acad. Sci. U. S. A. 92 1995 6269 6273
103. B. Viviani, S. Bartesaghi, F. Gardoni, A. Vezzani, M.M. Behrens, T. Bartfai, M. Binaglia, E. Corsini, M. Di Luca, C.L. Galli, and M. Marinovich Interleukin-1beta enhances NMDA receptor-mediated intracellular calcium increase through activation of the Src family of kinases J. Neurosci. 23 2003 8692 8700
104. S. Wang, Q. Cheng, S. Malik, and J. Yang Interleukin-1beta inhibits gamma aminobutyric acid type A (GABA(A)) receptor current in cultured hippocampal neurons J. Pharmacol. Exp. Ther. 292 2000 497 504
105. Y. Wang, M.F. Barbaro, and S.C. Baraban A role for the mTOR pathway in surface expression of AMPA receptors Neurosci. Lett. 401 2006 35 39
106. T. Weichhart, and M.D. Säemann The multiple facets of mTOR in immunity Trends Immunol. 30 2009 218 226
107. WHO Epilepsy, 2010. http://www.who.int/mediacentre/factsheets/fs999/en/ index.html (accessed 19.11.10.).
108. M. Wong Mammalian target of rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: from tuberous sclerosis to common acquired epilepsies Epilepsia 51 2010 27 36
109. O. Yalçin Genes and molecular mechanisms involved in the epileptogenesis of idiopathic absence epilepsies Seizure 21 2012 79 86
110. L.H. Zeng, L. Xu, D.H. Gutmann, and M. Wong Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex Ann. Neurol. 63 2008 444 453
111. L.H. Zeng, N.R. Rensing, and M. Wong Developing antiepileptogenic drugs for acquired epilepsy: targeting the mammalian target of rapamycin (mTOR) pathway Mol. Cell. Pharmacol. 1 2009 124 129
112. L.H. Zeng, N.R. Rensing, and M. Wong The mammalian target of rapamycin signaling pathway mediates epileptogenesis in a model of temporal lobe epilepsy J. Neurosci. 29 2009 6964 6972
113. B. Zhang, and M. Wong Pentylenetetrazole-induced seizures cause acute, but not chronic, mTOR pathway activation in rat Epilepsia 53 2012 506 511
114. Y.J. Zhang, Y. Duan, and X.F. Zheng Targeting the mTOR kinase domain: the second generation of mTOR inhibitors Drug Discov. Today 16 2011 325 331